Johnson & Johnson (JNJ)
What Johnson & Johnson Earnings Signal for Healthcare ETFs
With Q1 earnings season well underway, it was Johnson & Johnson (JNJ) giving investors a peek at how the broader healthcare sector might perform. The healthcare giant beat expectations on Tuesday in revenue ($24.1 billion actual versus $23.6 expected) and earnings per share ($2.70 actual versus $2.66 expected).
Johnson & Johnson's Spravato sales growth signals upside for psychedelics peers like AtaiBeckley
Johnson & Johnson (NYSE:JNJ)'s Spravato is reinforcing investor interest in the broader psychedelics sector as it reported another quarter of strong sales growth, with Jefferies analysts pointing to implications for companies such as AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) and peers developing next-generation mental health treatments. Spravato (esketamine nasal spray), which is approved for treatment-resistant depression (TRD), generated $468 million in global sales in the first quarter of 2026, representing a 46% increase year over year.
Johnson & Johnson Q2 Earnings Review: Why You Should Be Buying The Stock Today
Johnson & Johnson delivered a robust Q1, with revenues up nearly 10% YoY to $24.1bn and a raised full-year 2026 sales guidance above $100bn. JNJ's diversified portfolio—driven by double-digit growth in Innovative Medicines and strong growth in MedTech—positions it as "the cleanest growth story in healthcare." Most key products face minimal near-term patent risk, while new launches like icotrokinra, Rybrevant, and Inlexzo offer multibillion-dollar potential.
J&J Beats Q1 Earnings & Sales Estimates, Raises 2026 Outlook
JNJ tops Q1 earnings and sales estimates, lifts 2026 outlook as strong oncology and MedTech growth offset steep Stelara decline.
Johnson and Johnson Raises Dividend for 64th Consecutive Year
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) declared its 64th consecutive annual dividend increase on April 14, 2026, lifting its quarterly payout from $1.30 per share to $1.34 per share, a 3% increase.
Johnson & Johnson (JNJ) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Johnson & Johnson (JNJ) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Johnson & Johnson beats quarterly revenue estimates, maintains full-year outlook
Johnson & Johnson (NYSE:JNJ) reported first-quarter results on Tuesday that beat Wall Street expectations for revenue, driven by solid growth across its pharmaceutical and medical technology businesses. The healthcare conglomerate posted revenue of $24.06 billion for the quarter, up 9.9% from a year earlier and above analysts' estimates of $23.61 billion.
Johnson & Johnson (JNJ) Surpasses Q1 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.7 per share, beating the Zacks Consensus Estimate of $2.67 per share. This compares to earnings of $2.77 per share a year ago.
J&J raises guidance for 2026 on strong start to the year
The healthcare giant saw sales of medications, which include Darzalex and Tremfya, increase 11% in the first three months of the year
Growth vs. Stability: Lilly and J&J's 2026 Investment Face-Off
JNJ edges out LLY in a tight pharma showdown, backed by stronger valuation and stock performance despite Lilly's explosive GLP-1-driven growth.
Johnson & Johnson Q1 Earnings Preview: Time To Sell The Rally?
Johnson & Johnson stock is up 17% YTD and over 60% in the past twelve months, reflecting renewed investor confidence but also raising concerns about the sustainability of the rally. In this update on J&J - my first in nearly two years – I'll provide a brief preview of the first-quarter earnings report expected on Tuesday. More importantly, however, I will provide an update on JNJ's drug pipeline and growth prospects.
Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?
JNJ approaches Q1 results with strong drug growth and MedTech momentum. However, rising biosimilar competition and pricing pressures cloud the outlook.
